Cognition Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cognition Therapeutics
CGTX Stock  USD 1.24  0.08  6.06%   
Cognition Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cognition Therapeutics' valuation are provided below:
Market Capitalization
116.5 M
Earnings Share
(0.47)
We have found one hundred twenty available fundamental signals for Cognition Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cognition Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 30.4 M in 2026. Enterprise Value is likely to drop to about 4 M in 2026
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 187.9 K, Interest Expense of 21.4 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.4. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Cognition Stock
Check out the analysis of Cognition Therapeutics Correlation against competitors.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Cognition Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets34.7 M34.8 M19.2 M
Slightly volatile
Short and Long Term Debt Total696 K732.6 K5.2 M
Slightly volatile
Other Current Liabilities9.2 M8.8 M2.2 M
Slightly volatile
Total Current Liabilities8 M12.8 M5.8 M
Slightly volatile
Other Liabilities3.4 M4.4 M3 M
Slightly volatile
Property Plant And Equipment Net608.9 K780.9 K435.4 K
Slightly volatile
Current Deferred Revenue1.4 M1.2 M1.3 M
Very volatile
Accounts Payable3.2 M2.3 M2.6 M
Slightly volatile
Cash29.2 M28.8 M14.3 M
Slightly volatile
Non Current Assets Total926.4 K780.9 K556 K
Slightly volatile
Long Term Debt10.9 M14.8 M9.3 M
Slightly volatile
Cash And Short Term Investments29.2 M28.8 M14.3 M
Slightly volatile
Net Receivables2 M2.4 M3.3 M
Slightly volatile
Common Stock Shares Outstanding30.2 M45.7 M25.8 M
Slightly volatile
Liabilities And Stockholders Equity34.7 M34.8 M19.2 M
Slightly volatile
Non Current Liabilities Total292.4 K307.8 K41.3 M
Slightly volatile
Inventory2.4 M2.3 M846.5 K
Slightly volatile
Other Current Assets1.4 M2.1 M691 K
Slightly volatile
Other Stockholder Equity234.1 M222.9 M62.3 M
Slightly volatile
Total Liabilities9.8 M10.3 M46.7 M
Slightly volatile
Property Plant And Equipment Gross1.6 M2.1 M1.3 M
Slightly volatile
Total Current Assets33.8 M34 M18.6 M
Slightly volatile
Capital Stock72.5 K69 K17.4 K
Slightly volatile
Net Working Capital25.8 M21.2 M12.9 M
Slightly volatile
Short Term Debt600.6 K542.8 K274.3 K
Slightly volatile
Common Stock72.5 K69 K17.4 K
Slightly volatile
Property Plant Equipment177.6 K209.7 K260.7 K
Slightly volatile
Common Stock Total Equity23.2 K26.1 K28.5 K
Slightly volatile
Capital Surpluse124.7 M140.2 M153.1 M
Slightly volatile
Short and Long Term Debt388.5 K251.1 K570.9 K
Slightly volatile
Non Current Liabilities Other1.3 M1.5 M1.7 M
Slightly volatile

Cognition Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization187.9 K305.9 K132.2 K
Slightly volatile
Interest Expense21.4 K22.5 K765.2 K
Slightly volatile
Selling General Administrative10.5 M14.1 M6.6 M
Slightly volatile
Other Operating Expenses36.5 M62.1 M20 M
Slightly volatile
Research Development28.4 M47.9 M21.2 M
Slightly volatile
Cost Of Revenue187.9 K305.9 K132.2 K
Slightly volatile
Total Operating Expenses36.4 M62.1 M19.9 M
Slightly volatile
Reconciled Depreciation186.8 K305.9 K131.8 K
Slightly volatile
Total Other Income Expense Net19.5 M23 M15.6 M
Slightly volatile
Selling And Marketing Expenses201.6 K226.8 K247.6 K
Slightly volatile

Cognition Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.2 M4.3 M1.5 M
Slightly volatile
Begin Period Cash Flow25.2 M34.4 M13.4 M
Slightly volatile
Depreciation187.9 K305.9 K132.2 K
Slightly volatile
Capital Expenditures3.4 K3.6 K106.2 K
Slightly volatile
Change To Operating Activities475.4 K500.4 K797.5 K
Pretty Stable
Total Cash From Financing Activities17.5 M27.1 M9.7 M
Slightly volatile
End Period Cash Flow29.2 M28.8 M14.3 M
Slightly volatile
Change To Netincome2.6 M4.1 M1.7 M
Slightly volatile
Sale Purchase Of Stock5.6 M6.2 M6.8 M
Slightly volatile
Change Receivables373.6 K420.3 K458.8 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.01640.01731.1488
Slightly volatile
Inventory Turnover0.550.620.6797
Slightly volatile
Days Of Inventory On Hand422474518
Slightly volatile
Payables Turnover0.04170.06580.0466
Slightly volatile
Cash Per Share0.780.570.4957
Slightly volatile
Days Payables Outstanding8.5 K5.7 K8.7 K
Slightly volatile
Income Quality0.50.750.6307
Very volatile
Current Ratio3.162.392.7499
Slightly volatile
Capex Per Share1.0E-41.0E-40.0046
Slightly volatile
Interest Debt Per Share0.02310.02430.2635
Slightly volatile
Debt To Assets0.02940.0310.6611
Slightly volatile
Graham Number0.720.810.8869
Slightly volatile
Operating Cycle422474518
Slightly volatile
Days Of Payables Outstanding8.5 K5.7 K8.7 K
Slightly volatile
Ebt Per Ebit0.370.570.3615
Slightly volatile
Effective Tax Rate0.830.931.0171
Slightly volatile
Quick Ratio3.152.392.7306
Slightly volatile
Cash Ratio2.652.021.8583
Slightly volatile
Days Of Inventory Outstanding422474518
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0443
Pretty Stable
Debt Ratio0.02940.0310.6611
Slightly volatile

Cognition Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap30.4 M32 M200.1 M
Slightly volatile
Enterprise Value4 M4.2 M191.3 M
Slightly volatile

Cognition Fundamental Market Drivers

Cognition Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cognition Therapeutics Financial Statements

Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.2 M1.4 M
Cost Of Revenue305.9 K187.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
WDWalker Dunlop
GMGeneral Motors
GMGeneral Motors

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY